- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FDA Delays UCB’s Bimekizumab Approval
FDA action is no longer expected in Q3 of 2023.
This article was originally published by Dermatology Times. It has been lightly edited.
UCB has announced that it has received an Establishment Inspection Report from the FDA after a prelicense inspection conducted at its Belgium manufacturing facility in April 2023 regarding the production of Bimzelx (bimekizumab) for the treatment of adult patients with moderate to severe plaque psoriasis. The FDA has stated that the inspection is “successfully closed.”1
The FDA will continue to review UCB’s bimekizumab Biologics License Application (BLA) but has not provided any further details on a new timeline to take action. UCB no longer anticipates FDA action in Q3 of 2023.
As UCB waits for further details on bimekizumab’s approval, it will continue to work with the FDA to complete the full review of bimekizumab’s BLA and its label. According to UCB, “The next update for the bimekizumab BLA will be shared at the time of the FDA action. UCB’s previously communicated 2023 financial guidance range remains unchanged.”
In March of 2022, the FDA issued a complete response letter to UCB regarding it BLA for bimekizumab and stated that “it cannot approve the BLA in its current form.” At the time, preapproval inspection observations were made during the approval process that needed to be resolved before moving forward.2
In early 2021, the FDA gave UCB a Prescription Drug User Fee Act date of October 15, 2021,3 but then delayed the approval due to needing an on-site facility inspection, and the COVID-19 pandemic restricted travel to and inspections of the Belgium facility.4
References
1. UCB provides update on US regulatory review of bimekizumab. News release. UCB. September 20, 2023. Accessed September 20, 2023. https://www.ucb.com/stories-media/Press-Releases/article/UCB-Provides-Update-on-US-Regulatory-Review-of-Bimekizumab
2. Update on US FDA review of biologics license application (BLA) for bimekizumab. News release. UCB. May 13, 2023. Accessed September 20, 2023. https://www.ucb.com/stories-media/Press-Releases/article/Update-on-US-FDA-Review-of-Biologics-License-Application-BLA-for-bimekizumab-0
3. UCB announces PDUFA date for bimekizumab. News release. UCB. April 28, 2021. Accessed September 20, 2023. https://www.ucb-usa.com/stories-media/UCB-U-S-News/detail/article/ucb-announces-pdufa-date-bimekizumab
4. FDA misses PDUFA date for bimekizumab. Formulary Watch. October 19, 2021. Accessed September 20, 2023. https://www.formularywatch.com/view/fda-misses-pdufa-date-for-bimekizumab
CMS' 340B Repayment Proposal May Harm Vulnerable Hospitals, Reward Those With Higher Revenues
April 26th 2024The 340B hospitals not receiving an offsetting lump-sum payment from CMS following 2018-2022 cuts later ruled unlawful are disproportionately rural, publicly owned, and nonacademic, according to a new study.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More
